دورية أكاديمية

A Non-Toxic Binuclear Vanadium(IV) Complex as Insulin Adjuvant Improves the Glycemic Control in Streptozotocin-Induced Diabetic Rats.

التفاصيل البيبلوغرافية
العنوان: A Non-Toxic Binuclear Vanadium(IV) Complex as Insulin Adjuvant Improves the Glycemic Control in Streptozotocin-Induced Diabetic Rats.
المؤلفون: Lopes, Mateus S., Baptistella, Gabriel B., Nunes, Giovana G., Ferreira, Matheus V., Cunha, Joice Maria, Oliveira, Kauê Marcel de, Acco, Alexandra, Lopes, Maria Luiza C., Couto Alves, Alexessander, Valdameri, Glaucio, Moure, Vivian R., Picheth, Geraldo, Manica, Graciele C. M., Rego, Fabiane G. M.
المصدر: Pharmaceuticals (14248247); Apr2024, Vol. 17 Issue 4, p486, 19p
مصطلحات موضوعية: GLYCEMIC control, INSULIN, LABORATORY rats, BLOOD sugar, VANADIUM, RATS, HYPERGLYCEMIA, GLYCOSYLATED hemoglobin
مستخلص: Diabetes mellitus (DM) complications are a burden to health care systems due to the associated consequences of poor glycemic control and the side effects of insulin therapy. Recently. adjuvant therapies, such as vanadium compounds, have gained attention due to their potential to improve glucose homeostasis in patients with diabetes. In order to determine the anti-diabetic and antioxidant effects of the oxidovanadium(IV) complex (Et3NH)2[{VO(OH}2)(ox)2(µ–ox)] or Vox2), rats with streptozotocin (STZ)-induced diabetes were treated with 30 and 100 mg/kg of Vox2, orally administered for 12 days. Vox2 at 100 mg/kg in association with insulin caused a 3.4 times decrease in blood glucose in STZ rats (424 mg/dL), reaching concentrations similar to those in the normoglycemic animals (126 mg/dL). Compared to insulin alone, the association with Vox2 caused an additional decrease in blood glucose of 39% and 65% at 30 and 100 mg/kg, respectively, and an increased pancreatic GSH levels 2.5 times. Vox2 alone did not cause gastrointestinal discomfort, diarrhea, and hepatic or renal toxicity and was not associated with changes in blood glucose level, lipid profile, or kidney or liver function. Our results highlight the potential of Vox2 in association with insulin in treating diabetes. [ABSTRACT FROM AUTHOR]
Copyright of Pharmaceuticals (14248247) is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index
الوصف
تدمد:14248247
DOI:10.3390/ph17040486